Intrinsic value of Medical Transcription Billing - MTBC

Previous Close

$5.05

  Intrinsic Value

$6.41

stock screener

  Rating & Target

buy

+27%

Previous close

$5.05

 
Intrinsic value

$6.41

 
Up/down potential

+27%

 
Rating

buy

We calculate the intrinsic value of MTBC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  11.50
  10.85
  10.27
  9.74
  9.26
  8.84
  8.45
  8.11
  7.80
  7.52
  7.27
  7.04
  6.84
  6.65
  6.49
  6.34
  6.20
  6.08
  5.98
  5.88
  5.79
  5.71
  5.64
  5.58
  5.52
  5.47
  5.42
  5.38
  5.34
  5.31
Revenue, $m
  35
  39
  43
  48
  52
  57
  61
  66
  72
  77
  82
  88
  94
  101
  107
  114
  121
  128
  136
  144
  152
  161
  170
  180
  190
  200
  211
  222
  234
  246
Variable operating expenses, $m
  14
  16
  17
  19
  20
  22
  24
  25
  27
  29
  30
  32
  34
  36
  39
  41
  43
  46
  49
  52
  55
  58
  61
  65
  68
  72
  76
  80
  84
  89
Fixed operating expenses, $m
  25
  25
  26
  26
  27
  27
  28
  29
  29
  30
  30
  31
  32
  33
  33
  34
  35
  36
  36
  37
  38
  39
  40
  40
  41
  42
  43
  44
  45
  46
Total operating expenses, $m
  39
  41
  43
  45
  47
  49
  52
  54
  56
  59
  60
  63
  66
  69
  72
  75
  78
  82
  85
  89
  93
  97
  101
  105
  109
  114
  119
  124
  129
  135
Operating income, $m
  -3
  -1
  1
  3
  5
  7
  10
  12
  15
  18
  22
  25
  29
  32
  35
  39
  43
  47
  51
  55
  60
  64
  69
  75
  80
  86
  92
  98
  105
  112
EBITDA, $m
  0
  2
  5
  7
  10
  12
  15
  18
  21
  24
  27
  31
  34
  38
  42
  46
  50
  54
  59
  64
  69
  74
  80
  85
  91
  98
  105
  112
  119
  127
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
Earnings before tax, $m
  -3
  -2
  0
  2
  5
  7
  9
  12
  14
  17
  21
  24
  27
  30
  33
  37
  40
  44
  48
  52
  56
  61
  65
  70
  76
  81
  87
  93
  99
  106
Tax expense, $m
  0
  0
  0
  1
  1
  2
  2
  3
  4
  5
  6
  6
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  18
  19
  20
  22
  23
  25
  27
  29
Net income, $m
  -3
  -2
  0
  2
  3
  5
  7
  8
  10
  12
  15
  17
  20
  22
  24
  27
  29
  32
  35
  38
  41
  44
  48
  51
  55
  59
  63
  68
  72
  77

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  28
  31
  34
  38
  41
  45
  49
  52
  57
  61
  65
  70
  75
  80
  85
  90
  96
  102
  108
  114
  121
  127
  135
  142
  150
  158
  167
  176
  185
  195
Adjusted assets (=assets-cash), $m
  28
  31
  34
  38
  41
  45
  49
  52
  57
  61
  65
  70
  75
  80
  85
  90
  96
  102
  108
  114
  121
  127
  135
  142
  150
  158
  167
  176
  185
  195
Revenue / Adjusted assets
  1.250
  1.258
  1.265
  1.263
  1.268
  1.267
  1.245
  1.269
  1.263
  1.262
  1.262
  1.257
  1.253
  1.263
  1.259
  1.267
  1.260
  1.255
  1.259
  1.263
  1.256
  1.268
  1.259
  1.268
  1.267
  1.266
  1.263
  1.261
  1.265
  1.262
Average production assets, $m
  11
  12
  13
  14
  16
  17
  19
  20
  22
  23
  25
  27
  29
  30
  32
  35
  37
  39
  41
  44
  46
  49
  52
  54
  57
  61
  64
  67
  71
  75
Working capital, $m
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
Total debt, $m
  1
  1
  2
  3
  3
  4
  5
  6
  7
  7
  8
  9
  10
  11
  12
  13
  15
  16
  17
  18
  20
  21
  22
  24
  25
  27
  29
  31
  33
  35
Total liabilities, $m
  6
  6
  7
  8
  8
  9
  10
  11
  11
  12
  13
  14
  15
  16
  17
  18
  19
  21
  22
  23
  24
  26
  27
  29
  30
  32
  34
  35
  37
  39
Total equity, $m
  22
  25
  27
  30
  33
  36
  39
  42
  45
  49
  52
  56
  60
  64
  68
  72
  76
  81
  86
  91
  96
  102
  107
  113
  120
  126
  133
  140
  148
  155
Total liabilities and equity, $m
  28
  31
  34
  38
  41
  45
  49
  53
  56
  61
  65
  70
  75
  80
  85
  90
  95
  102
  108
  114
  120
  128
  134
  142
  150
  158
  167
  175
  185
  194
Debt-to-equity ratio
  0.040
  0.060
  0.080
  0.090
  0.110
  0.120
  0.130
  0.140
  0.150
  0.150
  0.160
  0.170
  0.170
  0.180
  0.180
  0.190
  0.190
  0.190
  0.200
  0.200
  0.200
  0.210
  0.210
  0.210
  0.210
  0.210
  0.220
  0.220
  0.220
  0.220
Adjusted equity ratio
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798
  0.798

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -3
  -2
  0
  2
  3
  5
  7
  8
  10
  12
  15
  17
  20
  22
  24
  27
  29
  32
  35
  38
  41
  44
  48
  51
  55
  59
  63
  68
  72
  77
Depreciation, amort., depletion, $m
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  13
  13
  14
  15
Funds from operations, $m
  0
  2
  4
  6
  8
  10
  12
  14
  16
  18
  20
  23
  25
  28
  31
  34
  37
  40
  43
  47
  50
  54
  58
  62
  67
  71
  76
  81
  86
  92
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from operations, $m
  0
  2
  4
  6
  8
  10
  12
  14
  16
  18
  20
  23
  25
  28
  31
  34
  37
  40
  43
  47
  50
  54
  58
  62
  67
  71
  76
  81
  86
  92
Maintenance CAPEX, $m
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -13
  -13
  -14
New CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
Cash from investing activities, $m
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -12
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -17
  -18
Free cash flow, $m
  -3
  -1
  1
  2
  4
  5
  7
  9
  10
  12
  14
  16
  18
  20
  23
  25
  28
  30
  33
  36
  39
  42
  45
  49
  53
  57
  61
  65
  69
  74
Issuance/(repayment) of debt, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
Issuance/(repurchase) of shares, $m
  6
  4
  2
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  7
  5
  3
  2
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
Total cash flow (excl. dividends), $m
  3
  4
  4
  4
  4
  6
  8
  9
  11
  13
  15
  17
  19
  21
  24
  26
  29
  31
  34
  37
  40
  44
  47
  51
  54
  58
  62
  67
  71
  76
Retained Cash Flow (-), $m
  -6
  -4
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -2
  0
  1
  1
  2
  3
  5
  6
  8
  10
  11
  13
  15
  17
  20
  22
  24
  27
  29
  32
  35
  38
  41
  45
  48
  52
  55
  59
  64
  68
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -2
  0
  1
  1
  1
  2
  3
  4
  5
  5
  5
  6
  6
  6
  6
  6
  5
  5
  5
  4
  4
  3
  3
  2
  2
  2
  1
  1
  1
  1
Current shareholders' claim on cash, %
  91.5
  86.4
  83.8
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9
  82.9

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company's offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

FINANCIAL RATIOS  of  Medical Transcription Billing (MTBC)

Valuation Ratios
P/E Ratio -5.6
Price to Sales 2.1
Price to Book 7.3
Price to Tangible Book
Price to Cash Flow -50.8
Price to Free Cash Flow -50.8
Growth Rates
Sales Growth Rate 4.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 57.1%
Total Debt to Equity 200%
Interest Coverage 0
Management Effectiveness
Return On Assets -32.7%
Ret/ On Assets - 3 Yr. Avg. -29.1%
Return On Total Capital -40.9%
Ret/ On T. Cap. - 3 Yr. Avg. -38.9%
Return On Equity -81.8%
Return On Equity - 3 Yr. Avg. -62.6%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 45.8%
Gross Margin - 3 Yr. Avg. 46%
EBITDA Margin -16.7%
EBITDA Margin - 3 Yr. Avg. -7.4%
Operating Margin -33.3%
Oper. Margin - 3 Yr. Avg. -25.8%
Pre-Tax Margin -37.5%
Pre-Tax Margin - 3 Yr. Avg. -27.2%
Net Profit Margin -37.5%
Net Profit Margin - 3 Yr. Avg. -29%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. -8.3%
Payout Ratio -11.1%

MTBC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MTBC stock intrinsic value calculation we used $31.810635 million for the last fiscal year's total revenue generated by Medical Transcription Billing. The default revenue input number comes from 0001 income statement of Medical Transcription Billing. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MTBC stock valuation model: a) initial revenue growth rate of 11.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MTBC is calculated based on our internal credit rating of Medical Transcription Billing, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Medical Transcription Billing.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MTBC stock the variable cost ratio is equal to 40.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $24 million in the base year in the intrinsic value calculation for MTBC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 18.5% for Medical Transcription Billing.

Corporate tax rate of 27% is the nominal tax rate for Medical Transcription Billing. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MTBC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MTBC are equal to 30.3%.

Life of production assets of 4.2 years is the average useful life of capital assets used in Medical Transcription Billing operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MTBC is equal to 1.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $20.25042 million for Medical Transcription Billing - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 11.846 million for Medical Transcription Billing is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Medical Transcription Billing at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
MDRX Allscripts Hea 9.90 36.76  str.buy
ATHN athenahealth 131.56 54.38  str.sell
MCK McKesson 130.15 340.66  str.buy
QSII Quality System 22.35 7.94  str.sell
NH NantHealth 1.43 0.02  str.sell
CERN Cerner 56.41 29.77  str.sell
CPSI Computer Progr 25.87 17.38  sell
INOV Inovalon Holdi 11.01 17.26  buy

COMPANY NEWS

▶ MTBC to Announce Q3 2018 Results on November 7, 2018   [Oct-22-18 09:00AM  GlobeNewswire]
▶ MicroCap Review Magazine Fall 2018 Issue Now Available   [Oct-09-18 08:30AM  ACCESSWIRE]
▶ MTBC Announces Partnership with Salus TeleHealth   [Sep-04-18 09:00AM  GlobeNewswire]
▶ MTBC First Half 2018 Shareholder Update   [Aug-17-18 08:45AM  GlobeNewswire]
▶ MTBC Announces Renewal of Top Hospital Client Contract   [Aug-09-18 09:00AM  GlobeNewswire]
▶ MTBC Brings Artificial Intelligence to Medical Practices   [Jul-25-18 09:00AM  GlobeNewswire]
▶ Universal EHR Solutions to Join MTBCs Blockchain   [Jul-18-18 09:00AM  GlobeNewswire]
▶ MTBC Successfully Closes Orion, Largest Acquisition to Date   [Jul-02-18 11:13AM  GlobeNewswire]
▶ MTBCs Orion Closing Scheduled for July 1   [Jun-29-18 02:49PM  GlobeNewswire]
▶ MTBC joins Russell Microcap Index   [Jun-25-18 09:00AM  GlobeNewswire]
▶ MTBC Announces Results from Annual Shareholders Meeting   [Jun-18-18 09:00AM  GlobeNewswire]
▶ Russell Microcap Index projected to add MTBC   [Jun-13-18 09:00AM  GlobeNewswire]
▶ MTBC: Off To Strong Start in 2018. Orion Deal Could Add Significant Value   [May-23-18 03:45PM  Zacks Small Cap Research]
▶ MTBC Reports First Quarter 2018 Results   [06:00AM  GlobeNewswire]
▶ MTBC: Zacks SCR Initiates Coverage of MTBC With $5.50/Share Price Target   [May-03-18 11:00AM  Zacks Small Cap Research]
▶ Founder and Former CEO of Practice Fusion Joins MTBC   [Apr-02-18 09:00AM  GlobeNewswire]
▶ talkEHR Signings Hit a New Milestone   [Mar-19-18 09:00AM  GlobeNewswire]
▶ Another retail fail: Dollar Tree stock tanks after earnings miss   [Mar-07-18 11:09AM  Yahoo Finance Video]
▶ MTBC Announces Top 10 Tradeshows for 2018   [Feb-05-18 09:00AM  GlobeNewswire]
▶ MTBC Full Year 2017 Shareholder Update   [Jan-09-18 09:00AM  GlobeNewswire]
▶ Penny Stocks to Watch for January 2018   [Jan-01-18 11:02AM  Investopedia]
▶ MTBC Announces Senior Leadership Team Promotions   [Dec-01-17 09:00AM  GlobeNewswire]
▶ Penny Stocks to Watch for December 2017   [Nov-30-17 11:02AM  Investopedia]
▶ MTBC Comments on 2017 Guidance and 2018 Outlook   [Nov-28-17 09:15AM  GlobeNewswire]
▶ MTBC Announces Joint Webinar with Physicians Trust   [Nov-17-17 09:15AM  GlobeNewswire]
▶ MTBC Offers SOAPware Users Free EHR and Practice Management   [Nov-08-17 07:00AM  GlobeNewswire]
▶ MTBC Reports Third Quarter 2017 Results   [06:00AM  GlobeNewswire]
▶ MTBC Discusses Achievement of Financial Milestones   [Oct-09-17 09:00AM  GlobeNewswire]
▶ Should You Buy Medical Transcription Billing Corp (MTBC) Now?   [Sep-22-17 11:51AM  Simply Wall St.]
▶ MTBC Announces Full Repayment of Opus Bank Term Debt   [Sep-11-17 07:00AM  Marketwired]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.